Clinical trial
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic…
NCT00104299 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00104299 |
|---|---|
| Title | Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis |
| Official title | Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI) |
| Acronym | RAVE |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Immune Tolerance Network (ITN) Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis |
| Intervention type | Drug |
| Interventions | Rituximab plus cyclophosphamide placebo (rituximab group), Cyclophosphamide plus rituximab placebo (control group), Azathioprine, Methylprednisolone (or other glucocorticoid), Prednisone |
| Enrollment | 197 |
| Start date | Jan 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Jan 1, 2010 |
| First posted | Feb 25, 2005 |
| Last update posted | Apr 21, 2017 |
| Countries | Netherlands, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: